Given that approximately 5% of NSCLC KRAS mutations localize at Q61 codons, this gap poses a significant risk of patient misclassification and loss of access to appropriate EGFR antibody therapies or enrollment in emerging KRAS-targeted trials [73,183]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.